Phase 1 N=59 A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.
Malaria
Primary: The Tolerability and Safety of Ascending Single Oral Doses of MMV533 — 5; 3; 7; 4 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=56 First in Human Study of a Monoclonal Antibody (SOL-116) Targeting BSSL (Bile Salt-Stimulated Lipase), Single and Multiple Dose Parts
Rheumatoid Arthritis
Primary: Safety and Tolerability: Adverse Events — 7; 9; 8; 8 number of events
Phase 2 N=324 Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
Non-Small-Cell Lung Cancer
Primary: Objective Response Rate (ORR) by PD-L1 Positive and Negative Levels - Part 1 — 41.3; 14.9 Percentage of participants
Phase 1 N=52 A Study of Tirzepatide (LY3298176) in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK) Part A: Area Under the Concentration Versus Time Curve [AUC (0-∞)] of Tirzepatide — 113000; 109000 nanograms*hours per milliliter(ng*hr/mL)